Vectors based on adeno-associated virus (AAV) are effective in gene delivery in vivo. Tissue-specific gene expression is often needed to minimize ectopic expression in unintended cells and undesirable consequences. Here, we investigated whether incorporation of target sequences of tissue-specific microRNA (miRNA) into AAV vectors could inhibit ectopic expression in tissues such as the liver and hematopoietic cells. First we inserted liver-specific miR-122 target sequences (miR-122T) into the 3¢-untranslated region (UTR) of a number of AAV vectors. After intravenous delivery in mice, we found that five copies of the 20mer miR-122T reduced liver expression of luciferase by 50-fold and b-galactosidase (LacZ) by 70-fold. Five copies of miR-122T also reduced mRNA levels of a secretable protein (myostatin propeptide) from the AAV vector plasmid by 23-fold in the liver. However, gene expression in other tissues, including the heart was not inhibited. Similarly, we inserted four copies of miR-142-3pT or miR-142-5pT, both hematopoietic lineage-specific, into the 3¢-UTR of the AAV-luciferase vector. We wished to see whether they could prolong transgene expression by inhibiting expression in antigen-presenting cells. However, in vivo luciferase gene expression in major tissues declined with time, regardless of the miR-142 target sequences used. Quantitative analysis of the vector DNA in various tissues revealed that the decline of transgene expression in vivo was mainly because of promoter shut-off other than loss of AAV-transduced cells by immune destruction. Moreover, transgene expression was not detected in circulating mononuclear cells after delivering AAV9 vector with or without miR142T. These results demonstrate that liver-specific miR-122 target sequence in AAV vectors was highly efficient in reducing liver expression, whereas hematopoietic miR-142 target sequences were ineffective in preventing decline of AAV vector gene expression in nonhematopoietic tissues resulted from promoter shut-off.
INTRODUCTION
Over the past decade, adeno-associated viruses (AAVs) have become vectors of choice for in vivo gene therapy of many genetic and chronic diseases such as hemophilia B, 1 Leber's congenital amaurosis, [2] [3] [4] Parkinson's disease, 5 hereditary muscular dystrophies [6] [7] [8] and alpha-1 antitrypsin deficiency 9 and so on. The lack of pathogenicity of the wild-type virus, broad-tissue tropism and persistence of vector DNA have bolstered AAV's potential as a potent delivery vehicle for in vivo gene therapy applications. 10 The first in vivo demonstration of long-term and persistent transgene expression by AAV was achieved without apparent immune reaction. 11 Subsequently, more evidence showed that AAV could mediate successful and sustained transgene expression in small animal models, 6, [12] [13] [14] [15] large animal models 16, 17 and even in human patients, 2, 3, 18 without noticeable side-effects. However, host immune responses to the capsids or to the transgene products have been noticed in large animal studies and in human clinical trials. Several factors may influence the development of an immune response to AAV, 19 including vector serotypes, route of administration, vector doses, host species, the presence of preexisting immunity and the specifications of the delivery cassette. In mice 20 and non-human primates, 21 the AAV2 serotype elicits a stronger immune response than the AAV7 or AAV8 serotypes. With respect to route of administration, systemic delivery of AAV vectors often results in immune tolerance and is less likely to induce an immune reaction to the transgene than intramuscular delivery. 22, 23 There is indication that the potential immune responses against AAV vectors are dose dependent. 24, 25 Host species is relevant because large animals and humans have more complex and diverse immune systems than small rodents, making them more prone to developing an immune reaction to AAV. 26 Preexisting neutralizing antibodies will reduce and even block AAV-mediated gene transfer. 27 The gene expression cassette, particularly the promoter and the nature of the transgene, will also affect immunogenicity. Tissue-specific promoters can reduce transgene expression in antigen-presenting cells and decrease the chances of developing an immune reaction to the transgene. 28 In addition, selected transgenes can elicit a potent humoral and/or cellular immune response, as in the case of ovalbumin transgene 29 and influenza virus hemagglutinin, which leads to complete clearance of cells expressing the gene, whereas other transgenes such as b-galactosidase elicit less immune response in normal mice. 30 Numerous efforts have been made to achieve strong tissue-specific expression using tissue-specific promoters and enhancers. 31 However, sometimes an enhancer from a different context could also lead to aberrant expression in undesirable tissues. For example, potent muscle-specific promoters with a strong myosin heavy chain (MHC) enhancer have the potential to generate leaky expression in the liver, a major depot for AAV vectors upon intravascular administration. 32, 33 Thus, aberrant liver expression of transgenes may result in side-effects or even immune responses, 34 although hepatic gene transfer has been shown to induce immune tolerance to several protein antigens. 22 MicroRNAs, first discovered in Caenorhabditis elegans, 35 are considered an essential component of the gene expression regulatory networks. Evolutionarily conserved, miRNAs are small non-coding regulatory RNAs involved in RNA-mediated gene silencing at the post-transcriptional level. 36 At present, more than 500 human miRNAs have been identified. 37 Mature miRNA binds specific mRNAs through target sequences located in the 3¢-untranslated region (UTR) that are either partially or fully complementary to the miRNA. Previously, it was believed that the expression of the corresponding gene was silenced or reduced either by mRNA degradation (if fully complementary) or inhibition of translation (if partially complementary). 38 More recently, it has been reported that miRNAs function predominately to reduce mRNA levels of nearly all targets. 39 Many miRNAs are expressed in a tissue-specific manner and have an important role in maintaining tissue-specific functions and differentiation. 40 Our study is intended to improve controlled gene expression by exploiting post-transcriptional regulation through endogenous tissuespecific miRNA systems, thus, to inhibit transgene expression in undesired tissues by incorporating tissue-specific miRNA target sequences into the 3¢-UTR of an AAV vector cassette. First, we investigated liver-specific miRNA target sequence miR-122T, as the liver is a major target organ by AAV. We found that miR-122T was able to effectively inhibited AAV gene expression in the liver. Subsequently, we also examined hematopoietic miRNA target sequences miR-142T, which could mediate inhibition of gene expression in hematopoietic lineage cells, including antigen-presenting cells. 41 However, we found that the miR-142T sequence could not prevent decline of gene expression in nonhematopoietic tissues, in which promoter shut-off, but not T-cell destruction of transgene expression cells had occurred.
RESULTS

Liver-specific miRNA-122 target sequence in AAV vectors diminished transgene expression in liver
MicroRNA-122, a 22-nucleotide miRNA, is derived from a liverspecific non-coding polyadenylated RNA transcribed from the gene hcr. 42 It is the most frequent miRNA isolated in the adult liver, representing approximately 70% of all cloned miRNAs there. 43 To test the efficacy of miR-122T in reducing unwanted AAV transgene expression in the liver, we synthesized either three or five copies of the target sequence (miRBase database accession number MI0008015) for incorporation into the 3¢-UTR of the firefly luciferase gene in AAV-CB-Luc vector ( Figure 1) .
We initially performed a hydrodynamic injection of naked plasmid DNA into mice (three in each group) to determine the inhibitory effect of miR-122T. Hydrodynamic gene delivery through tail-vein injection is an established and highly efficient procedure to deliver nucleic acids to the liver in small animals. 44 The mice were killed one day after plasmid injection, and their liver tissues were carefully dissected for luciferase activity analysis and DNA copy number determination. The luciferase activities were normalized by both plasmid DNA copy number and protein concentration. We found that the plasmid containing three copies of the target sequence (3ÂmiR-122T) caused a 10-to 50-fold reduction in luciferase expression, whereas the plasmid containing five copies (5ÂmiR-122T) caused a 20-to 100-fold reduction, when compared with the AAV-CB-Luc control plasmid without the miR-122T sequence (Figure 2a ). To further confirm that the inhibitory effect was liver specific, we transfected 293 cells, which did not express miR-122, using AAV-luciferase plasmids with or without miR-122T. No difference in luciferase activities was observed in the 293 cells transfected with the above plasmids (Figure 2b ), suggesting that the inhibitory effect of miR-122T was liver specific.
We subsequently packaged pAAV-CB-Luc and pAAV-CB-Luc-5ÂmiR-122T plasmids into AAV9, which was chosen for its superior ability to cross the blood vessel barrier and transduce cells in a broad range of tissues. 45, 46 The AAV9-CB-Luc-5ÂmiR-122T vector and the control AAV9-CB-Luc without miR-122T were delivered into 6-weekold imprinting control region (ICR) mice through tail-vein injection at a dose of 1Â10 12 vector genomes (v.g.) per mouse. The mice were killed and tissues were collected at 3 weeks after vector delivery. Luciferase activities were analyzed for skeletal muscles, cardiac muscle and the liver. As shown in Figure 3 , we did not observe difference in luciferase activities in the tibialis anterior muscles between the two groups. However, we did observe approximately 50-fold lower luciferase activities in the liver from mice injected with AAV9-CB-Luc-miR-122T (Po0.01, n¼5) as compared with control vector AAV9-CB-Luc-injected mice. Interestingly, we also observed significantly higher luciferase activities in cardiac muscle from mice injected with AAV9-CB-Luc-miR-122T (Po0.05, n¼5) as compared with AAV9-CB-Luc-injected mice ( Figure 3 ).
To further evaluate the effect of miR-122T on reducing liver transgene expression, we examined a different reporter gene and promoter, thus, the LacZ gene and the en-MHC-TNT promoter, which contains the troponin T promoter (TNT) and the MHC enhancer (en-MHC). The addition of en-MHC made the TNT promoter stronger in the heart, but it also made it very leaky in the liver. To reduce liver expression, we cloned five copies of miR-122T into the 3¢-UTR of the LacZ gene driven by the en-MHC-TNT promoter ( Figure 1 ). The pAAV-en-MHC-TNT-LacZ and pAAV-en-MHC-TNT-LacZ-5ÂmiR-122T plasmids were separately packaged into AAV9 vectors. The vectors were then delivered into 6-week-old ICR mice through tail-vein injection (3Â10 12 v.g. per mouse). Inhibiting transgene expression in liver by miRNA C Qiao et al
The mice were killed and their skeletal muscles, cardiac muscle and liver were collected at 3 weeks after vector delivery. The tissues were cryosectioned and subjected to 5-bromo-4-chloro-3-indolyl-b-Dgalactoside (X-gal) staining. We did not detect LacZ expression in the skeletal muscles from either group (data not shown), indicating that the en-MHC-TNT promoter, similar to its parental TNT promoter, was not active in the skeletal muscle. Surprisingly, the livers from mice injected with AAV9-en-MHC-TNT-LacZ showed very strong LacZ expression ( Figure 4a ), which was not seen with the parental TNT promoter ( Supplementary Figure 1) . On the other hand, the liver tissues from mice receiving AAV9-en-MHC-TNT-LacZ-5ÂmiR-122T showed only a few LacZ positive cells ( Figure 4a ). Consistent with the luciferase reporter gene vector, higher LacZ expression in the heart was also observed from the cassette containing 5ÂmiR-122T (compare Figures 3 and 4a ). Quantitative analysis of LacZ expression by the Chemiluminescent b-galactosidase assay kit (Applied Biosystems, Foster City, CA, USA, Cat #T1007) showed an approximately 70-fold decrease in LacZ expression in the liver in mice injected the vector containing the miR-122T, compared with those injected with vector without the miR-122T ( Figure 4b ).
Higher cardiac LacZ expression in the mice injected with AAV9-en-MHC-TNT-LacZ-5ÂmiR-122T was also observed (P¼0.06, n¼4). These data indicated that five copies of miR-122T into the 3¢-UTR of the AAV vector could effectively diminish liver expression.
MicroRNA with perfect complementarity to its target mRNA usually causes direct mRNA cleavage. 39 The miR-122T utilized in this study was a full-complementary sequence to the mature miR-122. We expected that the reduction of liver transgene expression by miR-122T occurs through mRNA degradation. To test this, we quantified the mRNA of the transgene by real-time PCR. Five copies of miR-122T were cloned into the 3¢-UTR of the pAAV-CAG-dog-MPRO-Ig plasmid, which contains a large (900 bp) intron ( Figure 5a ). We chose to use this construct because we could differentiate the size of the realtime PCR product of cDNA of spliced mRNA from the backbone vector DNA, which was 900 bp longer. The forward and reverse primers were designed to span the intron region ( Figure 5a ) with an expected RT-PCR product of 106 bp, whereas the vector DNA would be too large to be amplified by the qPCR program. The pAAV-CAGdog-MPRO-Ig-5ÂmiR-122T plasmid was delivered into adult mice liver through hydrodynamic injection (three mice per group), whereas control mice received the AAV-CAG-dog-MPRO-Ig plasmid. The mice were killed 24 h after plasmid delivery, and their liver samples were collected for RNA preparation. As shown in Figure 5b , the transgene mRNA quantity was reduced by 96% in the presence of the 5ÂmiR-122T, suggesting that the inhibition of liver expression by miR-122T occurred through mRNA degradation.
Examination of hematopoietic-specific miRNA target sequences for prolonged transgene expression in AAV vectors
One of the major hurdle for stable gene transfer in large animal models and human patients is the immune response against AAV vectors 26 and transgenes. 47, 48 Additionally, we have observed that some transgenes, such as luciferase, cannot retain long-term expression even in normal mice following systemic delivery of AAV vectors (unpublished data). We suspected that a cellular immune response against the luciferase might be developed during the course. In this study, we inserted hematopoietic-specific miRNA target sequences into the AAV vector in an attempt to downregulate the transgene expression in immune cells, consequently prolong the transgene expression in desired tissues. The strategy of suppressing transgene expression in antigen-presenting cells has been successfully utilized in 
Figure 3
Reduction in liver expression of luciferase resulting from incorporation of the liver-specific miRNA target sequence miR-122T into AAV9 vectors containing the luciferase reporter gene. AAV9-CB-Luc vectors with or without the miR-122 target sequence were injected into the tail veins of 6-week-old female ICR mice (1Â10 12 v.g. per mouse, n¼5). After 3 weeks, there was no difference between luciferase expression of TA muscles, 50-fold lower expression in miR-122T liver (**Po0.01), and significantly higher expression in miR-122T heart (*Po0.05). Error bars indicated s.d.
Inhibiting transgene expression in liver by miRNA C Qiao et al lentiviral vectors to avoid transgene-specific immunity. 49, 50 Four copies of miR-142-3pT or of miR-142-5pT were cloned into the 3¢-UTR of the pAAV-CB-Luc plasmid, which contains the luciferase gene driven by the ubiquitous chicken b-actin ((CB) promoter and cytomegalovirus enhancer) ( Figure 6a ). AAV9 vectors containing the above reporters were produced. As miRNAs are highly conserved, the miR-142-3p and miR-142-5p are identical among dog, mouse and human, respectively. 37 Therefore, if this strategy works in one species, it is likely to work in others as well.
Three groups of AAV vectors (AAV9-CB-Luc, AAV9-CB-Luc-4ÂmiR-142-5pT and AAV9-CB-Luc-4ÂmiR-142-3pT) were administered through tail-vein injection to the outbred ICR mice at a dose of 2Â10 12 v.g. per mouse and six mice per group. All the mice were killed at 3 months after vector injection and their tissues (tibialis anterior muscle, upper limb muscle, cardiac muscle and liver) were collected and assayed for luciferase activities. As shown in Figure 6b , we did not observe a statistically significant difference in luciferase expression among all groups, regardless the presence of the miRNA target sequences of hematopoietic lineage (P40.05, n¼6). We also observed significant intragroup variability in luciferase expression with a marked decline of transgene expression in several mice (Figure 6a ) in all groups. To reveal short-term transgene expression among different groups, we performed similar experiments and killed the mice at 2 weeks after vector delivery. We noticed 10-to 100-fold greater luciferase expression in tissues examined in the short-term study as compared with the relatively long-term study (Figure 6b , Po0.05), indicating a huge decline of long-term luciferase gene expression.
The decline of luciferase expression at 3 months after vector delivery, despite the presence of hematopoietic miRNA target sequences, could be because of either immune clearance or promoter shut-off. To determine the cause of this phenomenon, we performed real-time PCR to determine vector copy numbers and histology with immunofluorescent staining against the T lymphocyte marker CD4. If the decline in the transgene was because of an immune destruction against the AAV vector transgene-positive cells, we would observe an equivalent loss of vector DNA copy numbers, along with mononuclear cell infiltration and histopathology. Surprisingly, real-time PCR results revealed consistent AAV vector copy numbers in all mice studied for long-term groups, ranging from 10 to 80 copies per liver cell and 3 to 11 copies per nucleus for skeletal and cardiac muscles (Figure 6c ). More importantly, the short-term study showed similar vector copy numbers to the long-term study (Figure 6c, P40.05, n¼3-6.) . The data indicated that the decline of transgene expression in the longterm study was not because of immune rejection of the vector-positive cells. In addition, Hematoxylin and eosin staining displayed normal tissue histology and no apparent mononuclear cell infiltration in any tissue examined. Immunofluorescent staining against mouse CD4 Figure 4 Reduction in liver expression of LacZ mediated by miR-122T. (a) LacZ staining of liver and heart. AAV9 vectors (3Â10 12 v.g.) were delivered into 6-week-old ICR mice, which were killed 3 weeks later. Liver tissues showed much weaker LacZ expression when exposed to the miR-122 target sequence. Heart tissues showed stronger LacZ expression when exposed to the miR-122 target sequence. Scale bar: 100 mm. (b) Quantitative analysis of LacZ expression of liver and heart at 3 weeks after injection. Liver tissues exposed to the miR-122 target sequence showed a 70-fold decrease in LacZ expression (**Po0.001; n¼4). LacZ expression in heart tissues exposed to the miR-122 target sequence increased marginally over control (*P¼0.06). Error bars indicated s.d.
Inhibiting transgene expression in liver by miRNA C Qiao et al detected no significant CD4 + cells above the background control levels in all the tissues examined ( Supplementary Figure 2) . The intention of incorporating hematopoietic lineage-specific miRNA targeting sequence into AAV expression cassette in this study was to downregulate the transgene expression in antigenepresenting cells. To answer whether the transgene expressed in hematopoietic lineage cells, we analyzed the luciferase expression in mononuclear cells of blood circulation at different time points after delivering AAV9-CB-Luc vector with or without hematopoietic lineage-specific miRNA targeting sequence (three mice per group). AAV vectors with or without the hematopoietic miRNA targets (AAV9-CB-Luc, AAV9-CB-Luc-4ÂmiR-142-5pT and AAV9-CB-Luc-4ÂmiR-142-3pT) were administered through tail-vein injection in ICR mice at a dose of 2Â10 12 v.g. per mouse. At 36 and 96 h after vector delivery, blood was taken from each mouse through tailbleeding method. Previous studies indicated that it would take as short as 3 days for the transgene to reach approximately one-third of its peak level in vivo. 32 Mononuclear cells were isolated and subjected to luciferase activity analysis. The mononuclear cells isolated from different groups at various time point, all displayed background level of luciferase expression (data not shown), suggesting hematopoietic lineage cells were poorly transduced by the AAV9 vectors.
From above data, we concluded that (1) there was no significant T-cell immune responses in tissues of vector-treated mice; (2) the hematopoietic miRNA target sequences failed to prolong luciferase expression, which declined 3 months after vector delivery; (3) promoter shut-off, not immune rejection, was responsible for the decline of transgene expression in some individual mice. Incorporation of hematopoietic-specific miRNA-T in the 3¢-UTR of AAV9 vector was unable to help in this case.
DISCUSSION
To develop a safer AAV vector, we intended to utilize endogenous miRNA machinery to provide improved control of transgene expression at the post-transcriptional level. Specifically, we incorporated multiple copies of the liver-specific miR-122 target sequences into the 3¢-UTR of AAV expression cassette, for the purpose of decreasing unwanted liver expression. This strategy turned out to be highly effective. The reduction of luciferase expression mediated by 5ÂmiR-122T was 50-fold, whereas reduction of LacZ expression was over 70-fold. We did not observe any effects by miR-122T on transgene expression in the skeletal muscles. However, we did observe a slight but significant increase in cardiac muscle expression when AAV vectors containing 5ÂmiR-122T were used. The potential mechanism by which cardiac transduction was enhanced could be because of the presence of five copies of miR-122T in the 3¢-UTR of our vectors, which might increase mRNA stability in the cardiomyocytes or serve as a cardiac enhancer, as we did not notice similar phenomena in skeletal muscles. We further utilized quantitative PCR to demonstrate that mRNA degradation is the likely mechanism by which liver transgene expression was reduced.
One potential concern regarding this strategy is that a highly expressed transgene containing multiple binding sites for miR-122 could compete with endogenous targets for their cognate miRNA. However, this possibility is very unlikely for two reasons. First, the miRNA target sites are perfectly complementary, the miRISC will have a high catalytic rate, which reduces the likelihood of miR-122 from being titrated out. 41 Second, miR-122 is the most abundant miRNA in the liver, and possibly in the entire miRNA repertoire, making saturation improbable. Previous experiments have demonstrated that increasing concentrations of a perfectly complementary miRNA target site do not appreciably perturb miRNA regulation of an imperfect target. 41 In this study, we also used the hematopoietic lineage miR-142-3p or miR-142-5p target sequences in AAV expression cassettes in an attempt to decrease transgene expression in antigen-presenting cells and prolong transgene expression in normal mice. These sequences were effective in lentiviral vectors for prolongation of transgene expression. 41, 49, 50 However, the presence of the hematopoietic lineage miRNA target sequence in the AAV-CB-Luc vectors was not effective in preventing marked long-term decline of luciferase expression in the tissues after systemic delivery. Further investigation on vector copy numbers in transduced tissues, histology and lack of T-cell infiltration indicated that the decline in transgene expression was because of promoter shut-off. Cytomegalovirus promoter in AAV vector is prone to shut-off in the liver in 2-3 weeks after intravenous gene transfer. In this study, we utilized the chicken b-actin promoter (cytomegalovirus enhancer and CB promoter) that was reported to render long-term (46 months) green fluorescent protein gene expression in vivo in many tissues including the liver. 51, 52 However, the same promoter driving the luciferase gene expression caused short-term expression in major tissues examined in this study using the mice. We have observed similar results in hamsters (data not shown). It is likely that the luciferase gene and the high vector dose (10 12 v.g. per mouse, vs 2Â10 11 v.g. per mouse for the green fluorescent protein vector) both Inhibiting transgene expression in liver by miRNA C Qiao et al contributed to the promoter shut-off, which was likely caused by the innate immunity in the liver, other than the T-cell immunity. Utilizing AAV vectors driven by tissue-specific promoters without viral regulatory elements, and applying lower vector doses may prevent promoter shut-off in future experiments. Additionally, the barely detectable background levels of luciferase expression in mononuclear cells of AAV9-CB-Luc treated mice in our experiments indicates AAV9 similar to AAV8, 53 may not infect dendritic cells. It was also a possibility that the decline of the transgene expression was caused by activation of RNAi against the transgene, similar to RNAi against viral infection.
We cannot draw conclusions about the efficacy of hematopoietic miRNA target sequences in preventing an immune response against AAV-delivered transgenes because immune clearance was not the reason for the elimination of transgene expression in our experiments. A different species with a more complex immune system that is more prone to developing an immune response against AAV transgene expression, such as the dogs 47 and monkeys, 48 should be utilized to answer this question. Nevertheless, our study is an important attempt toward exploiting endogenous miRNA regulatory machinery to further control transgene expression mediated by the AAV vector at the post-transcriptional levels.
MATERIALS AND METHODS
Plasmid construction and AAV virus production
To construct luciferase plasmids containing miRNA target sequences, multiple copies of different target sequences were synthesized and cloned into NheI and SacI sites positioned in the 3¢-UTR of the AAV-CB-Luc plasmid 31, 54 (Figures 1  and 6 ). Their sequences are listed as follows: Cfa-4ÂmiR-122T: CCAGAAGCTT GCTAGCcaaacaccattgtcacactccaTCACcaaacaccattgtcacactccaGATATCcaaacacca ttgtcacactccaTCACcaaacaccattgtcacactccaAAGCTTGTAG. Cfa-4ÂmiR-142-5-pT-S: CCAGAAGCTTGCTAGCagtagtgctttctactttatgggTCACagtaggctttctactttatgggG ATATCagtagtgctttctactttatgggTCACagtagtgctttctactttatgggAAGCTTGTAG. Cfa-4ÂmiR-142-4Â3pT-S: CCAGAAGCTTGCTAGCtccataaagtaggaaacactacaTCAC tccataaagtaggaaacactacaGATATCtccataaagtaggaaacactacaTCACtccataaagtaggaaa cactacaAAGCTTGTAG. The lower case letters indicate the target sequences and the upper case letters are either linker sequences or restriction enzyme sites.
To construct the pAAV-en-MHC-TNT-LacZ plasmid, the BamHI-SalI fragment of the troponin T promoter (gene bank M57905.1) was cloned into BamHI and SalI sites of the pAAV-CMV-LacZ plasmid to replace the cytomegalovirus promoter, and the construction was named the pAAV-TNT-LacZ plasmid (Figure 1) . Then the EcoRI-HindIII fragment of the mouse a-MHC complex enhancer (en-MHC) (gene bank NW_001030560.1 from 1231272 to 1231460) was added in front of the TNT promoter of the pAAV-TNT-LacZ plasmid by cohesive ligation to form the pAAV-en-MHC-TNT-LacZ plasmid. Finally, the SalI-SphI fragment of the pAAV-CB-Luc-5ÂmiR-122T plasmid containing five copies of miR-122T and bovine growth hormone (BGH) polyA signal were cloned into SalI and SphI sites of the pAAV-en-MHC-TNT-LacZ plasmid to form the pAAV-en-MHC-TNT-LacZ-5ÂmiR-122T plasmid (Figure 1) .
The original AAV9 packaging plasmid was a generous gift from Dr James Wilson and Dr Guangping Gao. 46 All of the AAV vectors were produced by the triple-transfection method 55 and the viruses were purified by the secondgeneration CsCl protocol that incorporates differential precipitation of AAV particles by polyethylene glycol. 56 The virus titer was determined by both dot-blot and real-time PCR methods. 57, 58 Hydrodynamic injection of naked plasmid and AAV vector delivery in vivo All animal protocols were approved by the University of North Carolina at Chapel Hill Institutional Animal Care and Use Committee.
The detailed methods and mechanisms of hydrodynamic injection of plasmid DNA for delivery to liver cells have been described elsewhere. 44 Briefly, 50-100 mg of double-CsCl purified DNA was dissolved in 8-10% body weight volume of phosphate-buffered saline (PBS) (in ml) for a given mouse. For example, if the mouse weight was 25 g, we would dissolve 50 mg of DNA in 2 to 2.5 ml of PBS. The total volume of PBS-containing DNA was then injected into the tail veins of adult ICR mice (6-8 weeks old) over approximately 5 s, using 3 ml syringes and 27G Â ½ in PrecisionGlide Needles (BD, Franklin Lakes, NJ, USA, Cat #305109). The mice were killed at 24 h after injection when the peak of gene expression was achieved, and the liver tissues were carefully dissected and quickly frozen in isopentane-liquid nitrogen slurry for future analysis.
We utilized outbred ICR mice for most of the experiments described in this manuscript. Male ICR mice (6) (7) (8) week old) were purchased from Taconic (Hudson, NY, USA). For intravenous injection, mice were first warmed under an infrared heat lamp (100-160 W) for 5-10 min to dilate the tail vein. There was a significant decline of luciferase expression in long-term studied tissues comparing with the short-term counterparts (Po0.05). For the longterm study, AAV9-CB-Luc vectors with or without the miR-142 target sequences were injected into the tail veins of outbred ICR mice (2Â10 12 v.g. per mouse, n¼6), and tissues were collected 3 months later. For the short-term study, AAV9-CB-Luc vectors with or without the miR-142 target sequences were injected into the tail veins of C57BL/6 mice (1Â10 12 v.g. per mouse, n¼3), and tissues were collected 2 weeks later. (c) Tissue vector copy numbers in both long-term and short-term studies. There were no significant differences in tissue vector copy numbers between short-term and long-term studies (P40.05), ranging from 10-80 copies per liver cell and 3-11 copies per nucleus for skeletal and cardiac muscles.
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The desired dilution of AAV was prepared in PBS, and the appropriate dose was administered to the tail vein of mice held in a restrainer without anesthesia using a 27G Â ½ in PrecisionGlide needle.
Real-time PCR analysis
Two real-time PCR assays were utilized in this study. To determine the mechanism underlying the reduction in liver expression mediated by miR-122T, relative quantification real-time PCR was used. Total RNA was extracted from liver tissues with TRIzol Reagent from Invitrogen (Carlsbad, CA, USA, Cat #15596-026), and the first strand cDNA was synthesized utilizing the High-Capacity cDNA Reverse Transcription Kit with RNase Inhibitor from Applied Biosystems (Foster City, CA, USA, Part #4374966). For primers and probe designed for endogenous mRNA control, we utilized b-glucuronidase, which was purchased from Applied Biosystems (Cat # Mm00446953_m1). The primers and probe for pAAV-CAG-dog-MPRO-Ig molecules are listed as follows: RT-CAG (+): tctgactgaccgcgttactc; RT-CAG (À): ccgcggtggagctcaag; RT-CAG probe: FAM-cattttggcaaagaat-MGB.
To determine vector copy numbers in liver tissue, absolute quantification real-time PCR was used. Total DNA was extracted from liver tissues with the DNeasy Blood & Tissue Kit from QIAGEN (Valencia, Spain, Cat #69506). The mouse glucagon gene was used as the endogenous control. The sequences for mouse glucagon primers and probes were as follows: Glucagon-real-F (mouse): AAGGGACCTTTACCAGTGATGTG; Glucagon-real-R (mouse): ACTTACTCT CGCCTTCCTCGG; Taqman mouse glucagon probe: FAM-cagcaaaggaattca-MGB. For the target AAV9 vectors, primers and probes were designed on the common BGH polyA sequence. Their sequences were as follows: BGH-F: AGCCTCGACTGTGCCTTCTA; BGH-R: ATGCGATGCAATTTCCTCAT; BGH probe: FAM-TGCCAGCCATCTGTTG. The copy number of delivered vector in a specific tissue per diploid cell was calculated as: (vector copy number/ endogenous control)Â2.
Immunofluorescent staining against CD4
The snap-frozen tissues were cryo-thin sectioned at 8 mm thickness. Then the slides were fixed with acetone for 10 min followed by three washes with PBS. Blocking was performed with 5% horse serum in PBS for 30 min. The rat antimouse CD4 monoclonal antibody (Pharmingen International, San Diego, CA, USA, Cat #01061D) was incubated at a 1:500 dilution in 1X PBS for 1 h at room temperature. After three washes with 1X PBS, the secondary antibody Cy3-conjugated goat anti-rat IgG (Jackson ImmunoResearch, West Grove, PA, USA, Cat #706-165-1480) was incubated at a 1:500 ratio in 1X PBS. After another three washes with 1X PBS, the slides were incubated with 1X 4' ,6diamidino-2-phenylindole for 5 min to display the nucleus. Finally, the slides were mounted with the aqueous mounting medium Gel/Mount (Biomeda, Foster City, CA, USA, Cat #M01).
X-gal staining for expression of LacZ and LacZ activity analysis
For X-gal staining, the cryo-thin section slides were air-dried and fixed in X-gal fixative buffer containing 2% formaldehyde and 0.2% gluteraldehyde in PBS. After washing with PBS, the slides were subjected to X-gal staining buffer at 37 1C overnight. The X-gal staining buffer consisted of 0.1 M phosphate buffer (pH 7.3) supplemented with 2 mM MgCl 2 , 5mM potassium ferrocyanide (Sigma, St Louis, MO, USA, Cat #P-9287) and 5 mM potassium ferricyanide (Sigma, Cat #P-8131). Before use, X-gal was added at a final concentration of 1 mg ml À1 . 59 To quantitate LacZ expression, we utilized the Galacto-Light Plus kit (Applied Biosystems, Cat #T1007). The manufacturer's protocol was strictly followed. The relative units of LacZ activity were normalized by total protein concentration, which was assessed with the Bio-Rad Protein Assay (Bio-Rad Laboratories, Hercules, CA, USA, 94547 Cat #500-0006).
Luciferase activity assay
Tissues (25-100 mg) were lysed and homogenized in luciferase lysis buffer (0.05% Triton X-100, 0.1 M Tris-HCl, pH 7.8, 2 mM EDTA). The homogenized lysates were extensively vortexed and spun down at 4 1C for 2min. The supernatant was utilized for luciferase activity analysis. For blood samples, the mononuclear cells were isolated using Ficoll-Paque density gradients. Blood was diluted in a ratio of 1:1 with PBS, and layered onto Ficoll-Paque (Sigma Diagnostics, St Louis, MO, USA, Cat #Histopaque-1083) with the ratio of blood + PBS/Ficoll of 4:3. The blood was centrifuged at 1800 r.p.m. for 35 min at room temperature. The lymphocyte layer (buffy coat) was removed and washed twice in PBS at 1200 r.p.m. for 10 min each, following the same wash with RPMI 1640 media. The cells were lysed in 200 ml of luciferase lysis buffer. Following two cycles of freeze-thaw in dry ice-ethanol bath, the homogenized lysates were extensively vortexed and spun down at 4 1C for 2 min. Supernatant was utilized for luciferase activity assay. The analysis was performed according to a previously described protocol, 60 and the Luciferase Assay System (Cat #E1501) was purchased from Promega (Madison, WI, USA).
